#RootsAnalysis
Text
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030
Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market” report to its list of offerings.
Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.
To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.htmlhttps://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html.
Key Market Insights
15+ therapies have been / are being developed for the different type of porphyria
Treatment.
More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.
Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.
Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.
To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/porphyria-pipline-review/request-sample.html
Key Questions Answered
§ What are the prevalent R&D trends related to Porphyria?
§ What are the key challenges faced by stakeholders engaged in this domain?
§ What are the principal therapies developed by the companies in this domain?
§ Who are the leading industry and non-industry players in this market?
§ What are the key geographies where research on porphyria is actively being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html mailto:or email [email protected]
You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
4 notes
·
View notes
Text
Manufacturing Execution System Providers in Healthcare Market
Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at a compound annual growth rate of 36%.
It is important to consider that the constant management of such enormous volumes of data is a quite tedious process and challenging process. Specifically, management and handling of huge datasets in the healthcare industry often requires a large workforce of specialized personnel. According to the American Hospital Association, by 2026, there is likely to be a shortage of 3.2 million healthcare workers. The continuously growing data, coupled to the projected deficit of healthcare workers, would inadvertently generate pressure on healthcare manufacturers to adopt novel tools / technologies that can improve management efficiency and better utilize the available, expensive resources. Moreover, increasing complexity of healthcare manufacturing operations, along with growing stringency and frequent changes in regulatory requirements has created a dire need for adoption of automated solutions, such as manufacturing execution systems (MES). It is worth mentioning that, in the past few years, substantial acquisition activity has been reported in the manufacturing execution systems market, as players strive to become one-stop-shops, to cater to the diverse needs of the healthcare sector.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market/request-sample.html
In recent years, several healthcare stakeholders have actively undertaken initiatives to incorporate a manufacturing execution system into their production lines, with an aim to connect, monitor and control the complex manufacturing process. In addition, players are integrating advanced technologies, including internet of thing (IoT) and artificial intelligence (AI), in order to collect and analyze large volume of data from various sources, as well as to produce value in the form of insights, predictions and actions. According to industry experts, MES has the potential to reduce 10%-30% of the overall production cost depending on the type of industry. It has further been observed that companies are increasingly adopting cloud-based manufacturing execution system, to overcome the challenges associated with growing complexity of processes and global expansion of businesses. Specifically, cloud-based MES integrates real-time information of different production floors and promotes collaboration. Driven by the ongoing innovation in the industry, as well as the rise in demand for automated solutions, the manufacturing execution system providers market for the healthcare sector is likely to witness positive growth over the coming years.
For additional details, please visit
https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#manufacturing execution systems#manufacturing execution systems market#manufacturing execution#MES#Market Research#Market Insights#RootsAnalysis
0 notes
Text
TELERADIOLOGY SERVICES – HAS CREATED THE NEED FOR REMOTE PATIENT DIAGNOSIS
TELERADIOLOGY SERVICES – HAS CREATED THE NEED FOR REMOTE PATIENT DIAGNOSIS
The “Teleradiology Services Market, report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of teleradiology solutions in the diagnostic imaging industry, till 2030. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Teleradiology is a branch of telemedicine that uses…
View On WordPress
0 notes
Link
Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines.
0 notes
Text
Marketing Strategy Consulting Firm At Rootsanalysis
We provide marketing strategy consulting firm in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis covering the following parameters:
Technology evolution
Research and development
Existing market landscape
Future Commercial potential
Regulatory concerns
Regional growth drivers
Risks and opportunities
We specialize in analyzing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research /consulting services dedicated to serving our clients in the best possible way.
https://www.rootsanalysis.com/reports.html
1 note
·
View note
Text
The peptides and macrocycle drug discovery services market is estimated to be worth USD 1.5 billion in 2030, By Roots Analysis
Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.
Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.
The report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes:
§ A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services
§ An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size).
§ An in-depth analysis of peptide platform and library service providers, featuring information on their company details, purpose of the platform, type of peptide manufactured and platform access model.
§ Profiles of peptides and macrocycle drug discovery service providers, featuring information on the year of establishment, location of headquarters, peptide discovery service / platform portfolio, recent developments, and an informed future outlook.
§ An analysis of the partnerships that have been established in the recent past, covering mergers and acquisitions, research collaborations, R&D agreements, licensing agreements (related to both technology platforms and service providers) and other form of collaborations.
§ An analysis of proprietary display technologies developed by different drug discovery technology providers, based on the 2X2 matrix.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Type of peptides
§ Synthetic peptides
§ Biologic and recombinant peptides
§ Type of discovery steps
§ Target identification and validation
§ Hit identification
§ Lead generation
§ Lead optimization
§ Therapeutic Area
§ Oncological disorders
§ Metabolic disorders
§ Cardiovascular disorders
§ Infectious diseases
§ Urological disorders
§ Endocrine disorders
§ CNS disorders
§ Other diseases
§ Company Size
§ Small companies
§ Mid-sized companies
§ Large and very large companies
§ Key geographical regions
§ Europe
§ North America
§ Asia-Pacific and the Rest of the World
Key companies covered in the report
§ GenScript
§ JPT Peptide Technologies
§ CPC Scientific
§ IRBM
§ Creative Peptides
§ Pepscan
§ Interprotein
§ RA Pharmaceuticals
§ Pepticom
§ PeptiDream
§ Creative Biolabs
§ MeSCue-Janusys
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other Recent Offerings
1. DNA-Encoded Libraries: Platforms and Services Market, 2020–2030
2. Antibody Contract Manufacturing Market, 2020 – 2030
3. Global Autoinjectors Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
TIL-based Therapies Market by Roots Analysis
Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings.
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
§ A detailed assessment of the current market landscape of drug developers engaged in the development of TIL-based therapies.
§ An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions in this field, and a schematic world map representation engaged in the development of TIL-based therapies.
§ Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above).
§ An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity across oncological disease indications.
§ An analysis of the partnerships that have been established in the recent past.
§ An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies.
§ A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies.
§ An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
§ A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Target Indication
§ Acute Lymphoblastic Leukemia
§ Melanoma
§ Others
To request for sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html
§ Key Players
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
The research includes brief profiles, featuring an overview of the company, its financial information (if available), details related to its product(s), highlighting type of therapy and current development status, technology portfolio (if available), recent developments and manufacturing capabilities.
§ Cellular Biomedicine Group
§ Iovnace Biotherapeutics
§ Lytix Biopharma
§ Phio Pharmaceuticals
For additional details, please visit
https://www.rootsanalysis.com/reports/til-therapies-market.html or email [email protected]
You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://medium.com/@RootsAnalysis
LinkedIn: https://medium.com/@RootsAnalysis
Twitter: https://medium.com/@RootsAnalysis
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, By Roots Analysis
Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs
Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.
The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
§ A detailed review of the current landscape of companies offering contract manufacturing services.
§ Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.
§ A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
§ An analysis of the partnerships and expansions that have been established in this domain, in the recent past.
§ A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
§ A detailed proprietary 2×2 representation to assess the current market scenario
§ An analysis of the initiatives of big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Type of Product
§ API
§ FDF
§ Type of Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmid DNA, probiotics, microbiome-based biologics)
§ Type of Microbial Expression System
§ Bacteria
§ Yeast
§ Others (Algae and fungi)
§ Scale of Operation
§ Commercial
§ Preclinical / Clinical
§ Type of End User
§ Small Companies
§ Mid-sized Companies
§ Large / Very Large Companies
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
§ Middle East and North Africa
§ Latin America
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html
Key companies covered in the report
§ AGC Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ Northway Biotechpharma
§ Ology Bioservices
§ Porton Biopharma
§ Stelis Biopharma
For additional details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email [email protected]
You may also be interested in the following titles:
1. Drug Repurposing Service Providers Market, 2020 – 2030
2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora:
https://rootsanalysisinsights.quora.com/
0 notes
Link
0 notes
Link
The current focus of the users of this novel technology is primarily on upgrading individual operations to the continuous mode; as indicated earlier, some companies have already established bioprocessing lines with multiple continuous processes. Cost, (end product) quality, processing speed and operational flexibility are some of the primary driving factors of the gradual shift to continuous bioprocessing. The COVID-19 pandemic has also contributed to accelerating the adoption of continuous flow systems. Some of the existing challenges in this field include complexities related to defining continuous processes (especially those upstream to the fermentation step), and aligning the available equipment to operate as per current GMP requirements. Although an end-to-end continuous bioproduction line is still several years away, we believe that the opportunity for both innovators and service providers engaged in this domain is likely to grow in the foreseen future.
2 notes
·
View notes
Link
Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. In fact, new best practices and improved methods of procurement, processing and storage of biospecimens have also been introduced to the industry. The pharmaceutical industry has seen a significant shift towards outsourcing the bioanalytical services to leverage cost-effective methods and overcome the existing capacity constraints. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering biospecimen procurement and analytical services.
2 notes
·
View notes
Text
The clinical trials software market is projected to be growing at a CAGR of 14%
Given the limitations of current clinical trial approaches, including inefficient patient management and data handling, trial sponsors are increasingly opting for innovative technologies and software solutions for conducting clinical trials
Roots Analysis has announced the addition of “Clinical Trials Software Market, 2022-2035” report to its list of offerings.
Excessive capital expenditure and other complexities associated with the traditional clinical trials has imposed an enormous financial burden on the pharmaceutical industry. Virtual clinical trials software solutions have the potential to induce substantial digital changes in clinical research methodology, resulting in a more patient-centric, cost-effective and easy to manage approach.
To order this 270+ page report, which features 60+ figures and 50+ tables, please visit https://www.rootsanalysis.com/reports/clinical-trial-software-market.html
Key Market Insights
Over 70+ companies claim to provide clinical trials software
The companies offer clinical trials software with different features like electronic data capture, eCOA/ePRO and eConsent along with decentralized and virtual clinical trials and remote monitoring of the patients. Majority of the players based in North America offer clinical trials software followed by Europe and Asia-Pacific. Further, the market is dominated by the presence of mid-sized players (more than 40%) followed by small and large players.
Clinical trial management software
It is a well-known fact that clinical trials form an integral part of the overall drug development process, enabling innovators to assess safety and efficacy of their drug candidates / devices. These studies account for around 50% of the total time and capital invested in the development process
Since 2016, more than 120+ partnerships have been inked by service providers
Interestingly, the maximum number of partnership agreements were inked in 2021, majority of these were service agreements (44%), followed by acquisitions/mergers (26%). Further, most of the deals were inked with players based in North America (64%).
Over 30 mergers and acquisitions were reported in this domain, during the period 2016-2021
More than 85% of these were instances of acquisitions. Further, majority of the instances involved the companies based in North America and the maximum number of deals were inked in 2019.
Over USD 492.8 million has been invested by both private and public investors, since 2016
Majority of the companies (67%) engaged in this domain primarily received funding through venture capital rounds. Further, around 98% of the funding instances were reported by players headquartered in North America.
The market is expected to grow at an annual rate close to 14% over the coming decade
The opportunity is likely to be well distributed across clinical trials software on the basis of features of software (EDC, eCOA/ePRO and eConsent) and geographies (North America, Europe and Asia-Pacific). By 2035, the clinical trials software market in North America is anticipated to grow at a relatively faster pace (39%), followed by the market in Europe (21%).
Clinical trial management system : Driven by the substantial progress in this domain, encouraging virtual clinical trial results, and ongoing technological advancement, the clinical trials software market is anticipated to grow at a commendable pace in the mid to long term.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/clinical-trial-software-market/request-sample.html
Key Questions Answered
§ Who are the leading players engaged in the development of clinical trials software solutions?
§ Which region(s) will occupy the maximum market share in clinical trials software domain?
§ Who are the key venture capitalists / strategic investors funding the clinical trials software development initiatives?
§ Which partnership models are commonly adopted by stakeholders engaged in the development of clinical trials software solutions?
§ Which factors are likely to influence the evolution of this market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
By 2035, the financial opportunity within the clinical trials software market has been analysed across the following segments:
§ Features of Software
§ Electronic Data Capture
§ eCOA/ePRO
§ eConsent
§ Analysis by Geographical Regions
North America
Europe
Asia Pacific
The research includes profiles of key players (listed below); each profile features a tabulated overview of company, product portfolio, recent developments, and an informed future outlook.
§ Advarra
§ ArisGlobal
§ AssistRx
§ Clario
§ IBM
§ IQVIA
For additional details, please visit
https://www.rootsanalysis.com/reports/clinical-trial-software-market.html or email [email protected]
You may also be interested in the following titles:
1. Virtual Clinical Trial Service Providers Market, 2021-2030
2. AI-based Clinical Trial Solutions Providers Market, 2020-2030
3. Patient Recruitment and Retention Services Market (2nd Edition), 2021-2030
4. Virtual Clinical Trial Service Providers Market, 2020-2050
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#clinical trial management system#clinical trial management software#clinical trials software market#clinical trials software#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The container closure integrity testing services market is projected to grow at a CAGR of 7% till 2035
Patient safety is one of the critical aspects of pharmaceutical industry, which makes it imperative for drug manufacturers and packaging service providers to evaluate the integrity of drug formulations packed in various container closure systems
Roots Analysis has announced the addition of “Container Closure Integrity Testing Services Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the extensive study of the current landscape and the likely future potential of container closure integrity testing services, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
§ A detailed assessment of the overall market landscape of container closure integrity testing service providers based on a number of relevant parameters. In addition, it presents details of the companies, highlighting their year of establishment, company size, and geographical presence.
§ A detailed competitiveness analysis of container closure integrity testing service providers, taking into consideration several relevant parameters.
§ Tabulated profiles of the key players providing container closure integrity testing services, which are headquartered in North America and Europe. Each profile includes an overview of the company, information on the financial performance (if available), product portfolio, recent developments, and an informed future outlook.
§ A case study providing the list of equipment used by various manufacturers to test container closure integrity, highlighting their key features, type(s) of analytical method(s) offered, type(s) of container(s) tested, container material(s) of container closure integrity testing technologies.
§ A detailed competitiveness analysis of container closure integrity testing equipment, taking into consideration several relevant parameters.
§ A regional capability assessment framework, which compares the container closure integrity testing capability across key geographies, based on a number of parameters.
§ A detailed analysis of the various container closure integrity testing analytical techniques. It highlights the popularity of analytical techniques and offers a benchmark to compare analytical techniques.
§ A case study on the use of robotic machinery in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes. Further, it presents the profiles of industry players that provide such equipment for aseptic processing of pharmaceuticals.
§ An in-depth analysis to estimate the current and future demand of container closure integrity testing service based on various relevant parameters.
§ A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
§ By 2035, the financial opportunity within the container closure integrity testing services market has been analyzed across the following segments:
§ Analysis by Type of Container Closure System
Vials
Syringes
Cartridges
§ Analysis by Type of Container Material
Glass
Plastic
§ Analysis by Geographical Regions
North America
Europe
Press Release: Variation 1 (Format 2)
Europe
Asia Pacific
MENA
Latin America
Rest of the World
Europe
Asia Pacific
MENA
Latin America
Rest of the World
Key companies covered in the report:
§ Berkshire Sterile Manufacturing
§ Confarma
§ Curia
§ DDL
§ Eurofins
§ Nelson Labs
§ SGS
§ Stevanato Group
§ Wilco
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/container-closure-integrity-testing-services-market.html
Other recent offerings:
1. Sustainable, Biodegradable and Eco-Friendly Packaging Providers Market: Industry Trends and Global Forecast, 2021-2035
2. Novel Drug Reconstitution Systems Market: Industry Trends and Global Forecast, 2021-2030
3. Global Pharmaceutical Vials Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell Therapy Packaging Products and Services Market: Industry Trends and Global Forecast, 2021-2030
5. Pre-Sterilized / Ready-to-Use Primary Packaging Market: Industry Trends and Global Forecast, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
#Container Closure Integrity (CCI)#container closure integrity testing#packaging testing market#integrity test market.#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7%
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions
Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.
According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.
To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
Nearly 230 digital therapeutic solutions are currently available / under development
Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.
Over 85% of digital therapeutic solutions are intended to replace medication
Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.
220+ clinical trials, focused on digital therapeutics, have been registered since 2004
Around 80,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy of digital therapeutics, and generate real world evidence concerning their efficacy and safety. Close to 50% of such trials have been / are being conducted in the US.
Nearly USD 1.9 billion invested by both private and public investors in this domain
~85% of the total capital raised for digital therapeutics-related initiatives was from venture capital investors, featuring over 370 participants.
Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019
More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019. Majority of the instances captured in the report were focused on pilot product offering (29%) and research and development agreements (21%).
North America and Europe are anticipated to capture over 70% of the market share by 2030
The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (23.2%). In 2030, digital solutions targeting metabolic disorders are likely to represent the largest market share, in terms of revenues from product sales (26%), followed by those intended for mental health problems (20%) and neurological disorders (19%).
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/208/request-sample.html
One of the key objectives of the report was to estimate the existing digital health market size and the future opportunity for digital therapeutics developers over the next decade.
A discussion on affiliated digital health market trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
Key Questions Answered
§ Who are the leading players engaged in the development of digital therapeutic solutions?
§ What are the most popular therapeutic areas addressed by digital health solutions?
§ What are the key factors influencing the price of digital therapeutics?
§ What is the trend of capital investments in the digital therapeutics market?
§ Which partnership models are commonly adopted by stakeholders in this industry?
§ What type of marketing strategies are being adopted by developers in this domain?
§ How is the COVID-19 pandemic likely to impact the digital therapeutics market?
§ How is the current and future opportunity likely to be distributed across key market segments?
§ What are the anticipated future trends related to digital therapeutics?
The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:
§ Type of Solution
§ Standalone Software Application
§ Software Application + Device + Personal Coach
§ Software Application + Device + AI Support
§ Software Application + Device
§ Software Application + AI Support
§ Software Application + Personal Coach
§ Other Types of Solutions
§ Purpose of Solution
§ Medication Replacement
§ Medication Augmentation
§ Type of Therapy
§ Curative
§ Preventive
§ Business Model
§ Business to Consumer (Patients and Caregivers)
§ Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)
§ Therapeutic Areas
§ Cardiovascular Disorders
§ Chronic Pain
§ Mental Health Problems
§ Metabolic Disorders
§ Neurological Disorders
§ Respiratory Disorders
§ Sleep Disorders
§ Substance Use Disorders
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the world
The report features inputs from eminent industry stakeholders, according to whom, digital therapeutic solutions are likely to witness enhanced adoption due to their broader applicability, remote guidance and other advanced features, thereby, offering lucrative opportunities to their developers. The report includes detailed transcripts of the discussions held with following industry experts:
§ Eran Ofir (Co-Founder and Chief Executive Officer, Somatix)
§ Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
§ Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
§ Adam Kaufman (Chief Executive Officer, Canary Health)
§ Vijay Ravindran (Chief Executive Officer, Floreo)
§ Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
§ Amelie Janson (Communication Manager, Voluntis)
§ Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company)
The research covers brief profiles of key players engaged in the development of digital therapeutic solutions; other popular industry players featured in the report include:
§ Akili Interactive
§ Beats Medical
§ Big Health
§ Bold Health
§ Click Therapeutics
§ CureApp
§ dreem
§ Ehave
§ Ginger
§ Happify Health
§ inMotion VR
§ Kaia Health
§ Lark Health
§ Mahana Therapeutics
§ MindMaze
§ Noom
§ NOVOSI
§ Omada Health
§ Palo Alto Health Sciences
§ Pear Therapeutics
§ Vida Health
§ Welldoc
§ ZOLL Medical
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
You may also be interested in the following titles:
1. AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030
2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
3. Global Handheld Ultrasound Imaging Devices Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#digital health#digital health market#digital health market size#digital health market trends#Market Research#Market Insights#RootsAnalysis
1 note
·
View note
Text
RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY
Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives.
In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/278/request-sample.html
With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#RNAi therapeutics#RNAi therapies#RNAi technologies#RNAi therapeutics market#Market Research#Market Insights#RootsAnalysis
0 notes
Text
VIRAL VACCINE CELL CULTURE MEDIA: OVERALL MARKET LANDSCAPE
Innovation is considered to be one of the key drivers of the pharmaceutical industry. Over the past few decades, various technological advances and a few fortuitous discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of vaccines, which have demonstrated significant therapeutic potential.
Over time, vaccine research has evolved significantly, which is now being driven by several innovative technologies, including those involving the use of recombinant deoxyribonucleic acid (DNA) and nucleic acids. Further, with the discovery of more disease targets, players engaged in vaccine development have shifted their focus towards the development of vaccines that target a myriad of disease indications other than infectious diseases. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing.
A vaccine is a biological substance that is used to stimulate the host’s immune system against a specific disease. It is worth highlighting those vaccines are also referred to as immunizers, due to their ability to take advantage of the host’s natural immune system to prevent illnesses. Generally, the vaccines contain a weakened or an inactivated (killed) form of a virus / a small (in virulent) part of the virus, which is called the antigen. Vaccines help the immune system recognize the antigen as a foreign entity or invading germ, thereby, resulting in the production of antibodies. This process aids the immune system in generating a memory against the specific pathogen so that if the host is attacked by the same pathogen in the future, the body can generate an illicit response.
To request a sample copy / brochure of this report, please visit link
https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html
Viral vaccines were first produced in the early 1940s, using embryonated chicken eggs to replicate a broad variety of viruses. Over 30 human vaccines, manufactured using this technique, have been licensed; however, the production capacity associated with this method was limited due to the unavailability of fertilized eggs. Further, in 1950s, an alternative technology based on animal cell culture, which used primary cells as substrate, was developed. Then, in the late 1960s, continuous cell lines were recognized as suitable hosts for human vaccine production, however, the first production process using this technique was established in 1977. One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035.
Cell cultures can be broadly classified into two categories, namely adherent and suspension cell cultures.
§ Adherent Cell Culture: As the name suggests, these cells must be attached to a surface to grow. These cells can be cultured in flasks, roller bottles and other cell culture vessels capable of handling anchorage-dependent cell types. As most of the tissue-derived cells in the body require an extracellular matrix for growth and proliferation, this method provides scalable options, such as mimicking a microenvironment. In addition, some adherent platforms provide the benefit of visualization through a microscope.
§ Suspension Cell Culture: In this process, cells or cluster of cells are allowed to function and multiply in an agitated growth medium. Suspension cells can be cultured in small-scale vessels, such as spinner flasks or large-scale vessels (single-use bioreactors). These cells offer a vast range of scalability, thereby, making it a preferred option for manufacturers in order to increase their operational efficacy. In fact, the nutrients can be continually adjusted in these cell cultures, depending on their usage and need of the cells. However, suspension cell culture lacks the benefit of direct visualization. In addition, the shear force and stress exerted due to the continuous agitation of the media in suspension culture are detrimental to many cell types, especially anchorage-dependent primary and stem cells.
For additional details, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Viral vaccines#cell culture media#cell culture media market#vaccine#Market insights#Market Research#RootsAnalysis
0 notes
Last Seen Blogs
justyoutubeitaliathings
just youtube italia things
bonniesgirl
may
wuifankris
oh, you know.
coldbirdfury
Untitled